CLDN5 and neoplasm: Furthermore, we demonstrated, for the first time, an interesting TLR-4/Wnt modulation, suggesting that combined therapies that simultaneously enhance Wnt/Dkk-3/claudin-5 activity and inhibit TLR-4 pathway, might shift the balance from tumor growth stasis to cytotoxic therapeutic responses.